D1067v might function as a novel tumorpromoting genetic alteration, and potentially an oncogene, in certain cancers. Doctors backed by billionaire try cancer care revamp the star. Driver s polkinghorn was a radiation oncologist at. Drivers lead investor is horizons ventures li ka shing. Driver is a technology platform that connects people to treatments and. William polkinghorn, md is a radiation oncologist in san francisco, california. These mutations are generally observed in patients with phlike all that have crlf2 abnormalities, although jak2 mutations are also observed in approximately 15% of children with down syndrome all. We demonstrate that the androgen receptor ar regulates a transcriptional program of dna repair genes that promotes prostate cancer radioresistance, providing a potential mechanism by which androgen deprivation therapy synergizes with ionizing radiation. How curing cancer has become a machine learning problem nathan boley, head of engineering. Polkinghorn is on doximity as a doximity member youll join over a million verified healthcare professionals in a private, secure network. Although somatic mutations in the pi3k pathway genes pik3ca and pten are known to drive pi3k pathway activation and cancer growth, the significance of somatic mutations in other pi3k pathway genes is less clear. Sutcliffe mj, shuster jj, sather hn, et al high concordance from independent studies by the childrens cancer group ccg and pediatric oncology group pog associating favorable prognosis with combined trisomies 4, 10, and 17 in children with nci standardrisk bprecursor acute lymphoblastic leukemia. Driver, a startup seeking to connect patients with.
Petros giannikopoulos, and drivers lead investor is horizons ventures li ka shing. Is driver a story of fast fail or a cautionary tale against pursuing dtc. Prostate cancer represents a substantial clinical challenge because it is difficult to predict outcome and advanced disease is often fatal. Can this app help chinas forgotten cancer sufferers. Sep 06, 2018 drivers polkinghorn was a radiation oncologist at memorial sloankettering, one of the biggest cancer treatments centers in the u. Our ceo and cofounder, will polkinghorn, will kick off the night with an introduction to driver before our head of engineering, nathan boley and a few of our technical leads and engineers dive into the tech talk.
Driver, a startup seeking to connect patients with clinical trials, shuts. Significant differences in the location and timing of recurrence across medulloblastoma subgroups have potential treatment ramifications. American society of clinical oncology 2020 publications. We demonstrate that the androgen receptor ar regulates a transcriptional program of dna repair genes. William polkinghorn, a former faculty member of memorial sloan kettering cancer center, told stat that the companys early reliance on directtoconsumer sales didnt yield enough revenue to keep drivers business afloat, or inspire enough confidence among investors to secure another funding round. Pete has worked with a number of state and nationally ranked players. The platform, called driver, was founded in 2015 by two american physicians, william polkinghorn and petros giannikopoulos, with headquarters in both shanghai and san francisco. For cao ruizhe, the life or death drama of her fight with cancer plays out in a small windowless room. Polkinghorn is ceo at and has ownership interest including patents in driver group. Androgen receptor signaling regulates dna repair in prostate. Driver s polkinghorn was a radiation oncologist at memorial sloankettering, one of the biggest cancer treatments centers in the u. Childhood cancer genomics pdqhealth professional version. He speaks with bloombergs stephen engle on bloomberg. Polkinghorn says the problem with cancer treatment is that patients are limited by whatever diagnoses and treatment options are presented to them at whatever hospital they choose to go to.
Mar 03, 2016 activation of the phosphoinositide 3kinase pi3k pathway occurs widely in human cancers. Sawyers has provided expert testimony for coinventor of mdv3100 enzalutamide and is entitled to royalties. There is an air gap between knowledge and patients that has existed in cancer care since the 1850s, said driver cofounder will polkinghorn. Nonmember subscribers have online access to tables of contents, abstracts, fulltext searching, fulltext display, podcasts, document delivery, pdfs, links to medline and genbank, future tables of contents. Androgen receptor upregulation mediates radioresistance. Drivers highcost cancer care procurement app shutters. Specifically, intensified local posterior fossa therapy should be tested in the initial treatment of patients with shh. Philadelphia, pa developing a more robust approach to measure mutational burden is of central importance to improving the characterization of the molecular profile of tumor and may improve our ability to predict tumor progression or response to therapy in patients. Activating alterations of the ret kinase are therapeutically actionable oncogenic drivers across a variety of cancers. On the basis of this finding, we hypothesized that pik3c. A second opinion on a cancer diagnosis, from the comforts. William polkinghorn, md san francisco, ca doximity. A second opinion on a cancer diagnosis, from the comforts of.
Based in san francisco and shanghai, driver is a technology platform that connects cancer patients to treatments and knowledge, all over the world, to get more. Our ceo and cofounder, will polkinghorn, will kick off the night with an introduction to driver before our head of engineering, nathan boley and a few of our technical leads and engineers dive into the tech. One of the projects that driver is fully funding under the program has begun matching patients being treated at howard university to clinical trials at ncis inhouse cancer center in. Sep 07, 2018 will polkinghorn, cofounder and chief executive officer of driver, explains how the company aims to revamp cancer care. With an app for the patient and an app for the doctor, drivers platform enables any cancer patient. Harvard doctors backed by li kashing try a fix for cancer. Mum was under hospital admission when she passed, however the day she died, the staff administrated a morphine syringe driver into the thigh. Androgen receptor signaling regulates dna repair in. With bigname backing, driver launches to match cancer. The clinicaltrialmatching startup driver shut down on oct. D1067v by exome sequencing analysis of an egfrmutant nonsmall cell lung cancer nsclc tumor biopsy from a patient with acquired erlotinib resistance. Confirmed and durable responses to multikinase inhibitors with activity against ret can be achieved in a proportion of patients with retrearranged or retmutant cancers. Mar 21, 2019 there is an air gap between knowledge and patients that has existed in cancer care since the 1850s, said driver cofounder will polkinghorn.
Research at memorial sloan kettering cancer center mskcc has identified a subset of tnbc, which appears to have a similar underlying biology as er breast cancer. Petros giannikopoulos, and is the first technology platform to colaunch in the united states and china. New global technology platform, driver, launches to connect. Androgen receptor upregulation mediates radioresistance after.
Will polkinghorn, cofounder and chief executive officer of driver, explains how the company aims to revamp cancer care. Driver has also created a parallel app for oncologists, called drive for clinic, so they can easily access the latest research and treatment options by colleagues around the world. New global technology platform, driver, launches to connect cancer. Recurrence patterns across medulloblastoma subgroups. Although somatic mutations in the pi3k pathway genes pik3ca and pten are known to drive. Special member rates apply to member in training, allied physiciandoctoral scientist, affiliated health professional, and studentnononcology resident members. Pete polkinghorn joined the tennis staff in may of 2009 as the centers head tennis professional. William polkinghorn, a former faculty member of memorial sloan kettering cancer center, told stat that the. The company not only collected tumor samples to be sequenced and. Petros giannikopoulos, and driver s lead investor is horizons ventures li ka shing.
American society of clinical oncology 2020 publications and. A macmillian nurse later visited mum and the driver was changed to also include antisickness drugs as well as the pain releif and then within about 45 hours mum had passed away. While he would not reveal the companys burn rate, cofounder and ceo william polkinghorn blamed overstretch for its failure. New global technology platform, driver, launches to. Sequencing of prostate cancers identifies new cancer genes. Cancer clinical trials tech startup driver shutters two months. Advertise partner with us stat plus group subscriptions stat madness. Driver, a startup seeking to connect patients with clinical. Helen diller comprehensive cancer center, university of california, san francisco, san francisco, ca, usa. Significant differences in the location and timing of recurrence. Drivers network includes over 30 of the worlds leading cancer centers, including its founding members the. Tindall reports receiving commercial research grant from beckman coulter. He speaks with bloombergs stephen engle on bloomberg technology. Jak genes are the primary kinases that are found to be mutated.
At last, an agreement to buy athenahealth politico. Preclinical cellculture and animalmodel work has identified the role of the androgen receptor ar signaling pathway as a potential driver of tumor growth in this subset of cancers. Drivers highcost cancer care procurement app shutters shortly after. G polkinghorn, md is a medical oncology specialist in augusta, me and has been practicing for 36 years. Based in san francisco and shanghai, driver is a technology platform that connects cancer patients to treatments and knowledge, all over the world, to get more life. Apr 16, 2018 prostate cancer represents a substantial clinical challenge because it is difficult to predict outcome and advanced disease is often fatal. Full membership includes the jco and international corresponding members receive online access. Mutational burden is typically calculated as a direct enumeration. William polkinghorn radiation oncology resident memorial. Polkinghorn, a radiation oncologist by training who was previously on the faculty of memorial sloan kettering cancer center, cofounded driver in may 2015 with an old harvard medical. Sep 06, 2018 one of the projects that driver is fully funding under the program has begun matching patients being treated at howard university to clinical trials at ncis inhouse cancer center in bethesda, md. Oct 15, 2018 based in san francisco and shanghai, driver is a technology platform that connects cancer patients to treatments and knowledge, all over the world, to get more life. Technology platform offers new options to cancer patients.
Activation of the phosphoinositide 3kinase pi3k pathway occurs widely in human cancers. He graduated from case western reserve u, school of medicine in 1984 and specializes in. New global technology platform, driver, launches to connect cancer patients to the best treatments around the world. Polkinghorn is on doximity as a doximity member youll join over a million verified healthcare. He graduated from case western reserve u, school of medicine in 1984 and specializes in medical oncology. Activating point mutations in kinase genes are uncommon in highrisk ball. Medulloblastoma does not change subgroup at the time of recurrence, reinforcing the stability of the four main medulloblastoma subgroups. Nov 12, 2018 polkinghorn, a radiation oncologist by training who was previously on the faculty of memorial sloan kettering cancer center, cofounded driver in may 2015 with an old harvard medical school. Oct 19, 2018 driver has also created a parallel app for oncologists, called drive for clinic, so they can easily access the latest research and treatment options by colleagues around the world. Driver s lead investor is horizons ventures li ka shing. Philadelphia, pa developing a more robust approach to measure mutational burden is of central importance to. William polkinghorn, a former faculty member of memorial sloan kettering cancer center, told stat that the companys early reliance on directtoconsumer.
1372 1124 909 1243 1046 772 1364 914 1238 479 382 1395 622 1270 1016 969 915 703 137 1147 408 1242 724 440 1046 457 951 1336 533 984 668 1339 1503 241 244 694 403 519 1425 507 1362 579 466